Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01666171|
Recruitment Status : Unknown
Verified January 2013 by National Cancer Institute (NCI).
Recruitment status was: Not yet recruiting
First Posted : August 16, 2012
Last Update Posted : July 10, 2013
RATIONALE: Learning about the effect of metformin hydrochloride in breast density of women with early-stage breast cancer may help plan treatment.
PURPOSE: This trial studies changes in breast density in patients with early-stage breast cancer treated with metformin hydrochloride or placebo on CAN-NCIC-MA.32.
|Condition or disease||Intervention/treatment|
|Breast Cancer||Drug: metformin hydrochloride Other: clinical observation Other: diagnostic laboratory biomarker analysis Other: imaging biomarker analysis Other: medical chart review Procedure: digital mammography|
- To evaluate the change in percent mammographic density in contralateral (unaffected breast) from prior to the initiation of metformin hydrochloride (metformin) or placebo treatment through one year of therapy in patients with hormone receptor-negative breast cancer (i.e., not on endocrine therapy).
- To evaluate the change in percent breast density in contralateral (unaffected breast) from prior to the initiation of metformin or placebo treatment through two years of therapy in patients with hormone receptor-negative breast cancer (i.e., not on endocrine therapy).
- To evaluate whether baseline mammographic density correlates with baseline of fasting plasma insulin, glucose levels, and Homeostasis Model Assessment (HOMA) (collected on the treatment protocol CAN-NCIC-MA.32) (MA.32).
- To evaluate whether changes in dense area in response to metformin therapy from pre-treatment through two years of therapy correlate with changes in fasting plasma insulin, glucose levels, and HOMA (collected on the treatment protocol MA.32) over the same time period.
- To explore whether change in mammographic density for women on metformin is associated with risk of second primary breast cancer.
OUTLINE: Patients' mammograms taken at baseline and at approximately 1 and 2 years of metformin or placebo treatment are retrieved and analyzed for breast-density change. Pre-menopausal patients' menstrual cycle information is also collected at baseline and every 6 months for 2 years.
|Study Type :||Observational|
|Estimated Enrollment :||458 participants|
|Official Title:||Change in Mammographic Density With Metformin Use: A Companion Study to NCIC Study MA.32|
|Study Start Date :||August 2012|
|Estimated Primary Completion Date :||April 2013|
- Change in percent mammographic breast density in contralateral (unaffected) breast from baseline to 1 year using two-sample t-test or Wilcoxon rank-sum test
- Change in percent mammographic breast density in contralateral (unaffected) breast from baseline to 2 years using two-sample t-test
- Correlation between baseline mammographic density and baseline plasma fasting insulin, glucose levels, and HOMA using a scatter plot, correlation-coefficient estimation, and linear-regression method
- Correlation of changes in dense area in response to metformin therapy from pre-treatment to on treatment (at year 1 and year 2) with plasma fasting insulin, glucose levels, and HOMA using simple linear-regression method
- Correlation between mammographic density and the incidence of second primary breast cancer using correlation coefficient and scatter plot
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01666171
|Principal Investigator:||Marie E. Wood, MD||University of Vermont|